ArriVent BioPharma, Inc.

AVBP

Explore Our Financial Data > Companies > ArriVent BioPharma, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	AVBP
CIK	0001868279
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	18 CAMPUS BLVD., SUITE 100, NEWTOWN SQUARE, PA, 19073-3269
Website	arrivent.com
Phone	240-780-6356
CEO	Zhengbin (Bing) Yao
Employees	N/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	N/A
Pre-Tax Income	N/A
Net Income	N/A
Net Income to Common	N/A
EPS	N/A

View All

Balance Sheet

Cash	N/A
Assets	N/A
Liabilities	N/A
Common Equity	N/A
Liabilities & Equity	N/A

View All

Cash Flow Statement

Net Income	N/A
Cash From Operating Activities	N/A
Cash From Investing Activities	N/A
Cash From Financing Activities	N/A
Change in Cash	N/A

View All

Calculations

NOPAT	N/A
EBITDA	N/A
Price to Earnings	N/A
Price to Book	N/A
ROE	N/A

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight

DelveInsight's EGFR Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Non-small cell lung cancer (NSCLC), Colorectal cancer (CRC), Head and neck cancer (HNC), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging EGFR in

Article Link

The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight

Non-small cell lung cancer is increasingly evolving into a biomarker-driven market, with EGFR-mutated disease emerging as one of the most commercially significant segments. The space is dominated by blockbuster EGFR-targeted therapies such as TAGRISSO, which now generates nearly USD 6 billion annually, reinforcing the importance of precision medicine in NSCLC management.

Article Link

ArriVent BioPharma Reports First Quarter 2026 Financial Results

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent’s dual-targeting MUC16/NaPi2b tetravalent ADC, advances into the clinic and plans to dose its first patient in 2H 2026, initially for ovarian and endometrial cancers ARR-002’s superior anti-tumor activity and favorable tolerability vs. single-target or bivalent approaches in preclinical ovarian cancer models presented at AACRCash and investme

Article Link

A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate

ArriVent BioPharma (AVBP) stock is in focus after the FDA cleared its investigational new drug application for ARR-002, a dual-target antibody drug conjugate for ovarian and endometrial cancers. See our latest analysis for ArriVent BioPharma. Despite a 2.6% 1-day share price return decline and a 7.2% 7-day pullback, ArriVent BioPharma’s 30-day and 90-day share price returns of 14.53% and 31.98%, alongside a 38.70% year to date share price return and 46.08% 1-year total shareholder return,...

Article Link

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approachesPhase 1 initiation expected in the second half of 2026 NEWTOWN SQUARE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced clearance of an investigational new drug (IND)

Article Link